AbCellera Biologics(ABCL)宣布,预计将在2026年8月10日(周一)发布其候选药物ABCL635针对中度至重度更年期血管舒缩症状(VMS)的2期临床试验顶线数据。这一消息备受市场关注,标志着公司在女性健康领域的研发进程迈入关键节点。
AbCellera Biologics(ABCL)宣布,预计将在2026年8月10日(周一)发布其候选药物ABCL635针对中度至重度更年期血管舒缩症状(VMS)的2期临床试验顶线数据。这一消息备受市场关注,标志着公司在女性健康领域的研发进程迈入关键节点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.